All Articles

Volaris Group's acquisition of SureView Systems isn't just another deal. It's a strategic move that reveals the future of integrated enterprise security.

Autonomy taps 30-year Mercedes-Benz executive Fred Weick as CEO, signaling a strategic push to merge legacy auto expertise with its disruptive subscription model.

CraniUS Therapeutics secures up to $4M in NIH funding for its NeuroPASS device, a refillable implant aiming to revolutionize glioblastoma and CNS treatment.

A record share of Americans are relocating, fleeing high costs for the Sun Belt. This isn't just about sunshine; it's a strategic economic shift.

4DMT secures a complex $200M credit facility, choosing strategic debt over equity. We dissect the deal and what it signals for late-stage biotech financing.

Intercontinental Exchange is launching futures on central bank decisions and energy data, a bold move to financialize economic news itself.

A new audio series, 'Nature, Inc.', rejects TikTok-style snippets for deep, uncut stories. Is this the media rebellion we've been waiting for?

Projector maker XGIMI enters the AI wearables race with its MemoMind One. Beyond its optical prowess, its $20/month 'AI Long Memory' service will define its legacy.

A new SEC-registered digital security, YLDS, is now held by a federally chartered bank, signaling a major shift for institutional investment on the blockchain.

Futu Holdings faces a shareholder lawsuit after a $271M Chinese fine, highlighting the severe commercial risks of navigating regulatory gray areas abroad.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

In a landmark move, Strategy Inc. unveils a new capital framework, trading pure conviction for controlled financial engineering. Is this the blueprint for the future?

SandboxAQ is bringing its 'Large Quantitative Models' to Google Cloud, promising to slash R&D timelines by blending advanced AI with fundamental physics.

A Chinese court cleared Biocytogen’s core antibody platform, a ruling that is less about one patent and more about validating a new era of sovereign innovation.

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.

As National Safety Month concludes, experts argue that a people-first culture, not just compliance, is the key to reducing risk and unlocking real business value.

High-grade gold assays at La Flora are not just a win for Latin Metals, but a powerful validation of a de-risked exploration model reshaping junior mining.

A new robotic surgery center in Palm Beach promises a revolution in spine care. But behind the tech is a private equity strategy shaking up American healthcare.

A secretive deal in Norway for a green data center isn't just a lease. It's a blueprint for who will power the AI revolution, and how.